Table 1. Baseline characteristics of the... | American Society of Hematology

Table 1.

Baseline characteristics of the patients

Patient	Age/Sex	Disease phenotype	No. of prior standard chemotherapies	No. of prior auto-SCT	Months from last high-dose therapy to allo-SCT	Status at allo-SCT	Cytogenetics	CD4 count/μL prior to allo-SCT
1	56/F	IgG/L	4	2	13	RR	Δ 13	80
2	63/M	IgA/K	7	2	15	RR	Δ 13	234
3	69/F	IgG/K+MDS	9	2	3	RR	Δ 13+5q−	98
4	58/M	IgA/L	6	2	12	RR^*	Δ 13	100
5	62/M	IgA/L	3	1	8	NCR	Δ 13	363
6	68/M	IgA/L+MDS	6	1	24	RR	Δ 13+5q−	120
7	49/F	IgG/K	8	2	14	PR	Δ 13	139
8	45/M	IgE/L	6	1	3	RR^*	Complex^†	151
9	64/M	IgG/K	6	1	4	PR	Δ 13	55
10	54/F	IgG/K	6	1	13	RR^*	Δ 13	96
11	50/F	IgG/K	7	2	40	RR	Complex^†	152
12	47/F	Nonsecretory	4	1	18	RR	Δ 13	260
13	57/F	IgG/K	3	1	3	PR	Δ 13	410
14	42/M	IgA/K	3	1	4	PR	Δ 13	300
15	63/M	IgG/L	5	2	32	RR	Complex^†	420
16	38/M	IgG/K	3	1	3	NCR	Δ 13	310

Patient	Age/Sex	Disease phenotype	No. of prior standard chemotherapies	No. of prior auto-SCT	Months from last high-dose therapy to allo-SCT	Status at allo-SCT	Cytogenetics	CD4 count/μL prior to allo-SCT
1	56/F	IgG/L	4	2	13	RR	Δ 13	80
2	63/M	IgA/K	7	2	15	RR	Δ 13	234
3	69/F	IgG/K+MDS	9	2	3	RR	Δ 13+5q−	98
4	58/M	IgA/L	6	2	12	RR^*	Δ 13	100
5	62/M	IgA/L	3	1	8	NCR	Δ 13	363
6	68/M	IgA/L+MDS	6	1	24	RR	Δ 13+5q−	120
7	49/F	IgG/K	8	2	14	PR	Δ 13	139
8	45/M	IgE/L	6	1	3	RR^*	Complex^†	151
9	64/M	IgG/K	6	1	4	PR	Δ 13	55
10	54/F	IgG/K	6	1	13	RR^*	Δ 13	96
11	50/F	IgG/K	7	2	40	RR	Complex^†	152
12	47/F	Nonsecretory	4	1	18	RR	Δ 13	260
13	57/F	IgG/K	3	1	3	PR	Δ 13	410
14	42/M	IgA/K	3	1	4	PR	Δ 13	300
15	63/M	IgG/L	5	2	32	RR	Complex^†	420
16	38/M	IgG/K	3	1	3	NCR	Δ 13	310

RR indicates refractory relapse; NCR, near complete remission.

Patients who had never achieved CR.

Abnormal cytogenetics but no Δ 13.